{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6846e583cca944a48e6715d3/6aedbba6c60d9ce81374593a?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"CPHI Milan 2026: The Biosimilar Boom Has Flipped Supply And Demand - Himanshu Gadgil","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6846e583cca944a48e6715d3/1793964939601-6f3efcb2-0836-4760-9ac4-6ce8309e7be2.jpeg?height=200","description":"<p>This week on Making It In Manufacturing, Elliot Payne sat down again with Himanshu Gadgil, Ph.D., CEO of Enzene, at CPHI Milan 2026, where ARTO was the official podcast partner.</p><p><br></p><p>In this episode, Himanshu covers:</p><p><br></p><p>(00:54) Enzene&#39;s last 12 months: the Manufacturing Excellence Award, its New Jersey facility fully running with two suites, and a full technology transfer offer for anyone who wants to onshore manufacturing.</p><p><br></p><p>(02:12) Why Enzene is opening up its continuous manufacturing platform: to reach the tipping point where a lot more people adopt it.</p><p><br></p><p>(02:59) The biosimilar boom seen at CPHI this year, and why the supply and demand equation has flipped.</p><p><br></p><p>(04:30) How Enzene stands out: a platform built for India&#39;s price-sensitive market, so it was cost effective from the start.</p><p><br></p><p>(05:58) What comes next for EnzeneX®: from 200 litres to 1,000 litres in 2.0, then process analytics, its own media, and AI that makes process decisions dynamically.</p><p><br></p><p>(07:23) Intuition or data: how he makes decisions, and how AI gives the team very quick access to what the data is saying.</p><p><br></p><p>(08:59) The decisions that shaped Enzene: becoming a full CDMO, and moving into pet health, where it works with four of the top five pet health companies.</p><p><br></p><p>(10:13) The one process he would remove from pharma manufacturing.</p><p><br></p><p>Watch the full episode to hear why Himanshu believes the best cost of goods will win as so many biologics come off patent.</p><p><br></p><p>Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&amp;utm_medium=referral&amp;utm_campaign=hln27cpw-cl-arto</p><p><br></p><p>Follow ARTO</p><p><br></p><p>LinkedIn: https://www.linkedin.com/company/artotalent/</p><p><br></p><p>Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw</p><p><br></p><p>Instagram: https://www.instagram.com/arto.talent</p><p><br></p><p>TikTok: https://www.tiktok.com/@artotalent</p><p><br></p><p>Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245</p><p><br></p><p>Website: https://arto-talent.com/</p><p><br></p><p>Youtube: https://www.youtube.com/@artotalent</p><p><br></p><p>Himanshu Gadgil</p><p><br></p><p>LinkedIn: https://www.linkedin.com/in/himanshu-gadgil-3326307/</p><p><br></p><p>Elliot Payne</p><p><br></p><p>LinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/</p><p><br></p><p>Timestamps:</p><p><br></p><p>00:00 Introduction</p><p><br></p><p>00:54 Enzene&#39;s last 12 months</p><p><br></p><p>02:12 Opening up continuous manufacturing</p><p><br></p><p>02:59 The biosimilar boom</p><p><br></p><p>04:30 Winning on cost of goods</p><p><br></p><p>05:58 EnzeneX® 3.0 and beyond</p><p><br></p><p>07:23 Intuition, data and AI</p><p><br></p><p>08:59 Decisions that shaped Enzene</p><p><br></p><p>10:13 One thing to remove from the industry</p><p><br></p><p>#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #Biosimilars #ContinuousManufacturing #Biologics #CDMO</p>","author_name":"ARTO Talent"}